Activity of ceftazidime–avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance

Center for Disease Dynamics, Economics & Policy, 2015 Kliebe, 1985, Evolution of plasmid-coded resistance to broad-spectrum cephalosporins, Antimicrob Agents Chemother, 28, 302, 10.1128/AAC.28.2.302 Adler, 2016, The continuing plague of extended-spectrum β-lactamase-producing Enterobacteriaceae Infections, Infect Dis Clin North Am, 30, 347, 10.1016/j.idc.2016.02.003 Jacoby, 2009, AmpC beta-lactamases, Clin Microbiol Rev, 22, 161, 10.1128/CMR.00036-08 Fernández, 2012, Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance, Clin Microbiol Rev, 25, 661, 10.1128/CMR.00043-12 US Food and Drug Administration. 2015. Avycaz (ceftazidime–avibactam) package insert. NDA 206494. Product labeling: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206494s000lbl.pdf. Astra Zeneca. A phase III, randomized, multicentre, double-blind, double-dummy, parallel-group comparative study to determine the efficacy, safety and tolerability of ceftazidime–avibactam versus meropenem in the treatment of nosocomial pneumonia including ventilator-associated pneumonia in hospitalized adults. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2013–2016. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01808092 NLM Identifier: NCT01808092. van Duin, 2016, Ceftazidime/avibactam and ceftolozane/tazobactam: second generation β-lactam/β-lactamase combinations, Clin Infect Dis, 10.1093/cid/ciw243 Syue, 2016, New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance, Int J Antimicrob Agents, 47, 250, 10.1016/j.ijantimicag.2015.12.021 Díaz, 2010, Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study, J Clin Microbiol, 48, 2840, 10.1128/JCM.02147-09 Ruiz de Alegría, 2011, Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases in Spain: microbiological and clinical features, J Clin Microbiol, 49, 1134, 10.1128/JCM.02514-10 Conejo, 2008, Effect of porin loss on the activity of tigecycline against Klebsiella pneumoniae producing extended-spectrum beta-lactamases or plasmid-mediated AmpC-type beta-lactamases, Diagn Microbiol Infect Dis, 61, 343, 10.1016/j.diagmicrobio.2008.01.023 Miró, 2013, Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain, Eur J Clin Microbiol Infect Dis, 32, 253, 10.1007/s10096-012-1737-0 Pérez-Llarena, 2013, Characterization of the new AmpC β-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis, Antimicrob Agents Chemother, 57, 5158, 10.1128/AAC.00818-13 Clinical and Laboratory Standards Institute. 2015. M100-S25. Performance standards for antimicrobial susceptibility testing, 25th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA. European Committee on Antimicrobial Susceptibility Testing. 2016. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, valid from 2016-01-01. European Committee on antimicrobial susceptibility Testing, Vaxjo, Sweden. Karlowsky, 2016, Activity of ceftazidime–avibactam against extended-spectrum- and AmpC β-lactamase-producing Enterobacteriaceae collected in the INFORM Global Surveillance Study from 2012 to 2014, Antimicrob Agents Chemother, 60, 2849, 10.1128/AAC.02286-15 Pages, 2016, Role of the outer membrane and porins in susceptibility of β-Lactamase-producing Enterobacteriaceae to ceftazidime–avibactam, Antimicrob Agents Chemother, 60, 1349, 10.1128/AAC.01585-15 Tsai, 2011, Klebsiella pneumoniae outer membrane porins OmpK35 and OmpK36 play roles in both antimicrobial resistance and virulence, Antimicrob Agents Chemother, 55, 1485, 10.1128/AAC.01275-10 Dupont, 2016, Molecular characterization of carbapenem-non susceptible enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime–avibactam and aztreonam–avibactam combinations, Antimicrob Agents Chemother, 60, 215, 10.1128/AAC.01559-15 Lahiri, 2014, Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance, Antimicrob Agents Chemother, 58, 5704, 10.1128/AAC.03057-14